AIMZ Investment Advisors LLC held its stake in shares of Mylan N.V. (NASDAQ:MYL) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,821 shares of the company’s stock at the close of the second quarter. AIMZ Investment Advisors LLC’s holdings in Mylan N.V. were worth $304,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Global X Management Co. LLC increased its stake in shares of Mylan N.V. by 91.6% in the first quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after buying an additional 1,441 shares during the period. Doliver Capital Advisors LP acquired a new position in shares of Mylan N.V. in the second quarter valued at approximately $201,000. Eagle Global Advisors LLC acquired a new position in shares of Mylan N.V. in the second quarter valued at approximately $205,000. Sheaff Brock Investment Advisors LLC acquired a new position in shares of Mylan N.V. in the second quarter valued at approximately $210,000. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of Mylan N.V. in the second quarter valued at approximately $215,000. 71.97% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have recently issued reports on MYL shares. UBS AG reaffirmed a “buy” rating and issued a $46.00 price objective (down previously from $50.00) on shares of Mylan N.V. in a research note on Thursday, August 10th. Citigroup Inc. raised Mylan N.V. from a “neutral” rating to a “buy” rating and upped their price objective for the company from $36.00 to $42.00 in a research note on Wednesday, August 16th. Mizuho reaffirmed a “buy” rating and issued a $37.00 price objective (down previously from $53.00) on shares of Mylan N.V. in a research note on Sunday, August 20th. BMO Capital Markets reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Mylan N.V. in a research note on Friday, September 29th. Finally, ValuEngine raised Mylan N.V. from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $41.21.
COPYRIGHT VIOLATION NOTICE: “Mylan N.V. (MYL) Position Held by AIMZ Investment Advisors LLC” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/10/11/mylan-n-v-myl-position-held-by-aimz-investment-advisors-llc.html.
Mylan N.V. (NASDAQ:MYL) traded down 0.65% during trading on Wednesday, hitting $38.20. The company’s stock had a trading volume of 1,343,225 shares. The firm has a 50 day moving average of $32.53 and a 200 day moving average of $36.33. The firm has a market cap of $20.49 billion, a P/E ratio of 30.81 and a beta of 1.30. Mylan N.V. has a 12 month low of $29.39 and a 12 month high of $45.87.
Mylan N.V. (NASDAQ:MYL) last posted its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The business had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3 billion. During the same period last year, the firm posted $1.16 earnings per share. Mylan N.V.’s quarterly revenue was up 15.7% on a year-over-year basis. Equities research analysts predict that Mylan N.V. will post $4.58 earnings per share for the current year.
Mylan N.V. Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).
What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.